Replimune Group
Tracked across 4 events · 77 articles · First seen Jul 25, 2025 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: Replimune Group is the target of multiple class action lawsuits due to alleged false statements regarding its IGNYTE trial, which led to the United States — Food and Drug Administration deeming the trial inadequate.
Jul 25, 2025 · 26 articles
Domestic
President Donald Trump>>> has signed off on a plan to fire Marty Makary>>>, the Commissioner of the United States — Food and Drug Administration>>>. This decision follows a series of controversies and criticisms against Marty…
Impact: Replimune Group>>> is a biotechnology company whose melanoma therapy was twice rejected by the United States — Food and Drug Administration>>> under Marty Makary>>>'s leadership. News of Marty Makary>>>'s potential ouster caused its shares to rise.
May 08, 2026 · 7 articles
Domestic
Marty Makary resigned as Commissioner of the United States — Food and Drug Administration on May 12, 2026, after a contentious 13-month tenure. His departure followed sustained pressure from within the Donald Trump administration and…
Impact: Replimune Group is a pharmaceutical company whose cancer drug rejection by the United States — Food and Drug Administration under Marty Makary's leadership was criticized by The Wall Street Journal.
May 08, 2026 · 35 articles
Business
Impact: Dieter Weinand currently serves on the board of Replimune Group, and will reduce his board seats to focus on his role at Evotec.
Apr 07, 2026 · 9 articles
70
Marty Makary rejected therapy Replimune GroupTrump plans to fire FDA...
NEWSDESK
Track Replimune Group live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard